# sakP Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *sakP* gene encodes sakacin P (SakP), a class IIa bacteriocin produced by lactic acid bacteria, primarily *Lactobacillus sakei* and *Lactobacillus curvatus*, functioning as a ribosomally synthesized antimicrobial peptide with potent anti-listerial activity. - SakP's mechanism of action involves binding to the mannose phosphotransferase system (Man-PTS) on susceptible Gram-positive bacteria, leading to pore formation, membrane depolarization, and cell death, a distinct pathway from conventional antibiotics. - The *sakP* gene cluster is polycistronic and regulated by a quorum-sensing system involving a histidine kinase (SakT) and response regulator (SakU), with transcription activated by a σ54-dependent promoter. - Structural analysis reveals SakP as a 43-amino-acid peptide with an N-terminal YGNGV motif for receptor binding and a C-terminal amphipathic α-helix for membrane insertion and pore formation, stabilized by disulfide bonds. - Naturally occurring variants, such as SakP-H12Y, exhibit enhanced anti-listerial activity and a broader spectrum, highlighting the potential for engineered SakP in food preservation and as an alternative to antibiotics in combating antimicrobial resistance. - The clinical significance of *sakP* is primarily in food safety for preventing *Listeria monocytogenes* contamination and in mitigating antimicrobial resistance due to its unique pore-forming mechanism. --- ## Executive Summary & Key Metadata The *sakP* gene encodes sakacin P (SakP), a class IIa bacteriocin produced by specific strains of lactic acid bacteria (LAB), most notably *Lactobacillus sakei* and *Lactobacillus curvatus*. Unlike classical eukaryotic signaling genes, *sakP* is a prokaryotic structural gene whose product functions as a ribosomally synthesized antimicrobial peptide (bacteriocin) with potent anti-listerial activity. The clinical significance of *sakP* is not rooted in human oncogenesis but rather in its translational potential as a natural food preservative, an alternative to conventional antibiotics, and a model for understanding peptide-membrane interactions. The gene product, SakP, is a 43-amino-acid peptide with a conserved YGNGV consensus motif characteristic of the pediocin-like bacteriocin family. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | sakP (prokaryotic gene; no HGNC designation) | | **UniProt Accession** | P35618 | | **Representative PDB ID** | 1O0S (NMR structure of sakacin P) | | **Chromosomal Locus** | Plasmid-borne (pSAK1) or chromosomal in *L. sakei* LTH673; variable across strains | | **Primary Molecular Function** | Antimicrobial pore-forming peptide; inhibits *Listeria monocytogenes* and other Gram-positive pathogens | | **Disease & Pathology Associations** | Foodborne listeriosis prevention; emerging antimicrobial resistance (AMR) mitigation | | **Expression System** | *Lactobacillus sakei*, *Lactobacillus curvatus*, heterologous hosts (e.g., *E. coli*, *Lactococcus lactis*) | | **Peptide Length** | 43 amino acids (mature peptide) | | **Molecular Weight** | ~4.4 kDa | | **Isoelectric Point (pI)** | ~8.9 (basic peptide) | The *sakP* gene is a paradigm of bacteriocin-mediated microbial competition. Its product, SakP, acts by binding to the mannose phosphotransferase system (Man-PTS) on susceptible Gram-positive bacteria, leading to pore formation, membrane depolarization, and cell death. This mechanism has been extensively characterized through structural biology, mutagenesis, and biophysical studies. The gene's clinical relevance is expanding as antimicrobial resistance (AMR) threatens conventional antibiotics, positioning SakP as a lead candidate for next-generation antimicrobials and food safety applications. --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Gene Location and Context The *sakP* gene was first cloned and sequenced from *Lactobacillus sake* LTH673 by Tichaczek et al. (1994) [1]. The gene is located on a 50-kb plasmid designated pSAK1, although chromosomal homologs have been identified in other strains. The genetic organization of the sakacin P locus is polycistronic, comprising the structural gene *sakP* (also annotated as *sppA* in some strains) and accessory genes required for processing, transport, immunity, and regulation. The complete sakacin P gene cluster typically includes: - ***sakP*** (structural gene): Encodes the prepropeptide (precursor peptide) of 61 amino acids, comprising an N-terminal double-glycine leader sequence (18 residues) and the mature peptide (43 residues). - ***sakB*** and ***sakC***: Genes encoding the ATP-binding cassette (ABC) transporter and its accessory protein, respectively, responsible for leader peptide cleavage and secretion. - ***sakD***: Encodes a dedicated chaperone-like protein involved in immunity and transport. - ***sakE***: Immunity protein that protects the producer cell from its own bacteriocin. - ***sakT*** and ***sakU***: Genes involved in regulation and signal transduction. The promoter region upstream of *sakP* contains a conserved -10 (TATAAT) and -35 (TTGACA) box recognized by the alternative sigma factor σ54, which is unusual for bacteriocin genes. Transcription is induced by the quorum-sensing peptide pheromone (sakacin P-inducing peptide, or SakP-IP), which is itself encoded within the cluster. The regulatory cascade involves a two-component signal transduction system (histidine kinase SakT and response regulator SakU) that activates σ54-dependent transcription of the structural gene. ### 1.2 Promoter Architecture and Transcription Factor Binding Sites The *sakP* promoter (P*sakP*) spans approximately 200 base pairs upstream of the translational start site. Key regulatory elements include: - **σ54-dependent promoter elements**: The -24/-12 consensus sequences (GG-N10-GC) are located at positions -24 and -12 relative to the transcription start site (TSS). These elements are recognized by RNA polymerase associated with σ54 (RpoN). - **Enhancer-binding protein (EBP) binding sites**: The response regulator SakU binds to upstream activator sequences (UAS) located approximately 100–150 bp upstream of the TSS. These UAS elements contain inverted repeats (5'-TGTCA-N4-TGACA-3') that serve as docking sites for phosphorylated SakU. - **Quorum-sensing responsive element**: A 22-bp palindromic sequence overlapping the UAS that mediates pheromone-dependent activation. The promoter is tightly regulated and exhibits a biphasic expression profile: low basal expression during early exponential growth, followed by a sharp increase upon accumulation of the inducing pheromone in the extracellular milieu. ### 1.3 Alternative Splicing and Isoforms As a prokaryotic gene, *sakP* does not undergo alternative splicing. However, post-translational processing generates multiple molecular forms: 1. **Prepropeptide (61 aa)**: The full-length translation product containing the N-terminal leader peptide (18 aa) and the mature bacteriocin (43 aa). 2. **Mature SakP (43 aa)**: The biologically active form released after cleavage of the leader peptide at the double-glycine motif (Gly-Gly) by the ABC transporter SakB. 3. **SakP variants**: Naturally occurring variants with single amino acid substitutions have been identified in different strains. For example, *Lactobacillus curvatus* BCS35 produces SakP-H12Y, a variant with a tyrosine instead of histidine at position 12, which exhibits altered antimicrobial spectrum and potency [2]. ### 1.4 Comparative Genomics Comparative genomic analyses across *L. sakei* and *L. curvatus* strains reveal that *sakP* is highly conserved at the nucleotide level (>95% identity), with most polymorphisms occurring in the C-terminal region of the mature peptide. The gene's plasmid-borne nature facilitates horizontal gene transfer, and homologs have been detected in *Enterococcus*, *Pediococcus*, and *Leuconostoc* species. The presence of mobile genetic elements (insertion sequences, transposases) flanking the sakacin P cluster suggests that the locus is a genomic island acquired through horizontal transfer. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Boundaries The mature SakP peptide (UniProt P35618) is 43 amino acids long with the following sequence: **NH₂-Tyr-Gly-Asn-Gly-Val-Tyr-Cys-Asn-Lys-Lys-Cys-Trp-Val-Asp-Trp-Gly-Gln-Ala-Ser-Gly-Cys-Ile-Gly-Gln-Thr-Val-Val-Gly-Gly-Trp-Leu-Gly-Gly-Ala-Ile-Pro-Gly-Lys-Ala-Thr-Thr-Ile-Asn-His-COOH** The peptide can be divided into three structural domains: 1. **N-terminal domain (residues 1–17)**: Contains the conserved YGNGV motif (residues 2–6) and a disulfide bridge between Cys9 and Cys14. This domain forms a β-sheet-like structure that is essential for target recognition and initial binding to the Man-PTS receptor. 2. **Central hinge region (residues 18–23)**: A flexible loop connecting the N-terminal β-sheet to the C-terminal α-helix. This region is critical for conformational flexibility and membrane insertion. 3. **C-terminal domain (residues 24–43)**: Forms an amphipathic α-helix that penetrates the lipid bilayer of target cells. This domain contains a second disulfide bridge (Cys24–Cys44 in some variants) and is responsible for pore formation and membrane disruption. ### 2.2 Secondary and Tertiary Structure Nuclear magnetic resonance (NMR) spectroscopy studies (PDB: 1O0S) have resolved the three-dimensional structure of SakP in solution. The peptide adopts a compact, largely unstructured conformation in aqueous solution but undergoes a conformational change upon interaction with membrane mimetics (e.g., dodecylphosphocholine micelles or liposomes). Key structural features: - **N-terminal β-hairpin**: Residues 2–17 form a twisted β-hairpin stabilized by the Cys9–Cys14 disulfide bond. The YGNGV motif is solvent-exposed and forms the primary receptor-binding interface. - **C-terminal α-helix**: Residues 24–43 adopt an amphipathic α-helix with a hydrophobic face (Leu28, Val31, Gly32, Ala35, Ile37) and a hydrophilic face (Gly26, Gly29, Gly33, Lys38, Thr39, Thr40, Asn41, His43). This amphipathic character is essential for membrane insertion. - **Disulfide bridges**: Two intramolecular disulfide bonds (Cys9–Cys14 and Cys24–Cys44) stabilize the overall fold. Reduction of these bonds results in complete loss of antimicrobial activity, underscoring their structural importance. ### 2.3 Quaternary Structure and Oligomerization SakP functions as a monomer in solution but is proposed to oligomerize upon binding to the Man-PTS receptor on target membranes. The current model suggests that multiple SakP monomers cooperatively assemble into a barrel-stave or toroidal pore, with the C-terminal α-helices forming the pore lumen and the N-terminal domains anchoring the complex to the receptor. The stoichiometry of the active pore complex is estimated to be 4–6 monomers based on electrophysiological and fluorescence quenching experiments. ### 2.4 Interactive 3D Visualizer For a comprehensive exploration of the SakP three-dimensional structure, including domain architecture, disulfide bond topology, and surface electrostatic potential, use the interactive visualizer below: [Interactive 3D Protein Visualizer: Load sakP (PDB: 1O0S)](/tools/protein-structure-viewer?source=direct&pdbId=1O0S) The visualizer supports multiple rendering modes (cartoon, surface, electrostatic potential), residue-level annotations, and structural alignment with homologous bacteriocins (e.g., pediocin PA-1, leucocin A). --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Biosynthesis and Secretion Pathway The production of SakP follows a dedicated biosynthetic pathway that is tightly regulated by quorum sensing: ```mermaid sequenceDiagram participant Producer as "L. sakei (Producer Cell)" participant Pheromone as "SakP-IP (Inducing Pheromone)" participant HK as "Histidine Kinase (SakT)" participant RR as "Response Regulator (SakU)" participant RNAP as "RNA Polymerase (σ54)" participant Ribosome as "Ribosome" participant Transporter as "ABC Transporter (SakB/C)" participant Target as "Target Cell (L. monocytogenes)" Producer->>Pheromone: Secretes basal levels of SakP-IP Pheromone->>HK: Binds to extracellular sensor domain HK->>HK: Autophosphorylation (His residue) HK->>RR: Phosphotransfer (Asp residue) RR->>RNAP: Phosphorylated SakU binds UAS, activates σ54-RNAP RNAP->>Ribosome: Transcribes sakP mRNA Ribosome->>Transporter: Synthesizes prepropeptide (61 aa) Transporter->>Transporter: Cleaves leader peptide (GG motif) Transporter->>Target: Secretes mature SakP (43 aa) Target->>Target: SakP binds Man-PTS receptor Target->>Target: Pore formation, membrane depolarization, cell death ``` ### 3.2 Quorum-Sensing Regulation The sakacin P system is regulated by a classic three-component quorum-sensing circuit: 1. **Signal production**: The inducing pheromone SakP-IP (a 22-amino-acid peptide) is constitutively produced at low levels and secreted via the general secretion pathway. 2. **Signal detection**: SakP-IP binds to the extracellular domain of the membrane-embedded histidine kinase SakT, triggering autophosphorylation at a conserved histidine residue. 3. **Signal transduction**: The phosphoryl group is transferred to an aspartate residue on the response regulator SakU. Phosphorylated SakU dimerizes and binds to the UAS elements upstream of the *sakP* promoter, recruiting σ54-RNAP and activating transcription. This regulatory circuit ensures that SakP is produced only when the producer cell density is high, minimizing metabolic burden during early growth phases. ### 3.3 Mechanism of Antimicrobial Action The antimicrobial activity of SakP is mediated through a multi-step mechanism: 1. **Receptor recognition**: SakP specifically binds to the mannose phosphotransferase system (Man-PTS), a sugar transporter present on the surface of susceptible Gram-positive bacteria. The N-terminal YGNGV motif is the primary receptor-binding determinant. The Man-PTS IIC and IID subunits form the docking site for SakP. 2. **Conformational change**: Upon receptor binding, SakP undergoes a conformational rearrangement, transitioning from a disordered state to a folded, membrane-competent conformation. 3. **Membrane insertion**: The C-terminal amphipathic α-helix inserts into the cytoplasmic membrane, with the hydrophobic face interacting with lipid acyl chains and the hydrophilic face lining the pore. 4. **Pore formation**: Multiple SakP monomers oligomerize to form a pore complex, leading to leakage of ions and small metabolites, dissipation of the proton motive force, and ultimately cell death. The specificity of SakP for Man-PTS explains its narrow spectrum of activity, which is primarily directed against *Listeria* species and other closely related Firmicutes. ### 3.4 Protein-Protein Interaction Networks SakP interacts with several protein partners during its biosynthesis and action: - **SakB (ABC transporter)**: Cleaves the leader peptide and exports the mature bacteriocin. - **SakD (accessory protein)**: Facilitates transporter function and may contribute to immunity. - **SakE (immunity protein)**: Binds to SakP and prevents pore formation in the producer cell. - **Man-PTS IIC/IID (target receptor)**: The primary target on susceptible cells. The immunity protein SakE is particularly interesting: it is a small, membrane-anchored protein that likely binds to the Man-PTS–SakP complex, sterically blocking pore assembly. This mechanism is distinct from that of other bacteriocin immunity proteins, which often sequester the bacteriocin in the periplasm. --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutational Analysis of SakP Although *sakP* is not a human disease gene, extensive mutational analyses have been conducted to map structure-function relationships and optimize its antimicrobial activity. Key hotspot mutations and their phenotypic consequences are summarized below: | **Mutation** | **Domain** | **Effect on Activity** | **Reference** | |---|---|---|---| | Y2A | N-terminal (YGNGV motif) | Complete loss of antimicrobial activity; abrogates receptor binding | [1] | | G4A | N-terminal (YGNGV motif) | 90% reduction in activity; disrupts β-hairpin conformation | [1] | | C9S | N-terminal (disulfide bridge) | Loss of activity; structural destabilization | [1] | | H12Y | N-terminal (loop) | Enhanced activity against *Listeria*; altered receptor specificity | [2] | | W18A | Hinge region | 70% reduction in activity; impaired membrane insertion | [1] | | G32A | C-terminal α-helix | 50% reduction in activity; disrupted helix packing | [1] | | K38A | C-terminal α-helix | 30% reduction in activity; altered electrostatic interactions | [1] | ### 4.2 Naturally Occurring Variants The SakP-H12Y variant produced by *L. curvatus* BCS35 is a notable naturally occurring mutant [2]. This variant exhibits: - **Enhanced anti-listerial activity**: The substitution of histidine with tyrosine at position 12 increases the peptide's hydrophobicity and improves its interaction with the Man-PTS receptor. - **Broader antimicrobial spectrum**: SakP-H12Y shows activity against additional Gram-positive pathogens, including *Enterococcus faecalis* and *Staphylococcus aureus*. - **Increased proteolytic stability**: The tyrosine residue confers resistance to certain proteases, extending the peptide's half-life in food matrices. ### 4.3 Clinical and Food Safety Implications The clinical significance of *sakP* mutations lies in their impact on food safety and antimicrobial resistance: - **Listeriosis prevention**: SakP and its variants are highly effective against *Listeria monocytogenes*, a foodborne pathogen with a mortality rate of 20–30%. The use of SakP-producing starter cultures in fermented meats and cheeses has been shown to reduce *L. monocytogenes* counts by 3–4 log cycles [3, 4]. - **AMR mitigation**: The emergence of antibiotic-resistant *Listeria* strains has prompted interest in bacteriocins as alternative antimicrobials. SakP's distinct mechanism of action (pore formation via Man-PTS) makes cross-resistance with conventional antibiotics unlikely. - **Biotechnological applications**: Recombinant SakP variants with enhanced activity and stability are being developed for use in clinical settings, including topical formulations for wound infections and oral antimicrobials for gastrointestinal pathogens. ### 4.4 Differential Diagnosis and Detection In clinical microbiology, the detection of SakP-producing LAB is relevant for: - **Quality control in food production**: PCR-based assays targeting the *sakP* gene are used to screen starter cultures for bacteriocin production. - **Probiotic characterization**: The presence of *sakP* is a marker for strains with potential probiotic and biopreservative properties [5]. - **Antimicrobial susceptibility testing**: SakP is used as a reference compound in assays to evaluate the susceptibility of *Listeria* isolates to class IIa bacteriocins. --- ## 5. Host-Pathogen & Viral Interactions (If Applicable) ### 5.1 Interaction with *Listeria monocytogenes* The primary host-pathogen interaction involving SakP is its antagonistic relationship with *L. monocytogenes*. The molecular basis of this interaction is the specific binding of SakP to the Man-PTS of *Listeria*. The Man-PTS is a multi-subunit complex (IIA, IIB, IIC, IID) that transports glucose and other sugars. SakP binds to the IIC and IID subunits, which are embedded in the cytoplasmic membrane. The interaction is characterized by: - **High affinity**: The dissociation constant (Kd) for SakP binding to Man-PTS is in the nanomolar range, reflecting the specificity of the interaction. - **Irreversibility**: Once bound, SakP induces a conformational change in the Man-PTS that leads to pore formation, making the interaction functionally irreversible. - **Species specificity**: SakP shows potent activity against *Listeria* species but is less effective against other Gram-positive bacteria, reflecting differences in Man-PTS sequence and structure. ### 5.2 Immune Evasion and Modulation While SakP itself is not a virulence factor, its production by LAB can modulate host immune responses. The study by Hu et al. (2009) [6] demonstrated that LAB-derived products, including bacteriocins, can influence dendritic cell maturation and function. Specifically, exposure to LAB supernatants containing bacteriocins was shown to: - **Downregulate pro-inflammatory cytokines**: Reduced production of IL-12 and TNF-α in LPS-stimulated dendritic cells. - **Alter surface marker expression**: Modulated the expression of CD80, CD86, and MHC class II molecules. - **Enhance regulatory T-cell responses**: Promoted the differentiation of tolerogenic dendritic cells, potentially contributing to the anti-inflammatory effects of probiotics. These findings suggest that SakP-producing LAB may have immunomodulatory properties beyond their direct antimicrobial activity, with potential applications in inflammatory bowel disease and other immune-mediated disorders. ### 5.3 Viral Interactions There are no known direct interactions between SakP and viral proteins. However, the use of SakP-producing LAB as probiotics has been investigated in the context of viral infections: - **Antiviral adjuvant**: LAB producing SakP may enhance mucosal immunity and provide non-specific protection against viral pathogens by modulating the gut microbiome. - **Food safety during viral outbreaks**: The use of SakP-producing starter cultures in fermented foods can reduce the risk of secondary bacterial infections in immunocompromised individuals during viral pandemics. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 SakP as a Therapeutic Agent SakP and its derivatives are being developed as antimicrobial agents for various clinical applications: | **Application** | **Development Stage** | **Formulation** | **Target Pathogen** | |---|---|---|---| | Food preservation | Commercialized | Purified peptide or producer strain | *Listeria monocytogenes* | | Topical antimicrobial | Preclinical | Hydrogel or cream | *Staphylococcus aureus*, *Enterococcus* spp. | | Oral antimicrobial | Preclinical | Capsule or liquid formulation | *Clostridium difficile*, *Salmonella* spp. | | Veterinary medicine | Research | Feed additive | *Listeria*, *Erysipelothrix* | ### 6.2 FDA-Approved and Investigational Drugs While no SakP-based drug has received FDA approval, several bacteriocin-based products are in various stages of development: - **Nisin (Nisaplin®)**: A related lantibiotic bacteriocin approved as a food preservative (E234). Nisin has also been investigated for clinical applications, including topical treatment of mastitis and gastrointestinal infections. - **Pedicin PA-1 (ALTA™ 2431)**: A class IIa bacteriocin closely related to SakP, approved as a food additive in several countries. - **SakP-based formulations**: Investigational products combining SakP with other antimicrobials (e.g., lysozyme, EDTA) are being evaluated for enhanced efficacy against Gram-negative pathogens. ### 6.3 Small-Molecule Inhibitors and Synergistic Combinations The therapeutic potential of SakP can be enhanced through combination with other agents: - **EDTA and citric acid**: These chelating agents disrupt the outer membrane of Gram-negative bacteria, sensitizing them to SakP. - **Lysozyme**: Synergistic activity against *Listeria* and other pathogens by degrading peptidoglycan and facilitating SakP access to the cytoplasmic membrane. - **Essential oils**: Plant-derived compounds (e.g., carvacrol, thymol) show additive or synergistic effects with SakP against foodborne pathogens [5]. ### 6.4 Resistance Mechanisms and Mitigation The emergence of SakP-resistant *Listeria* strains is a concern for long-term applications. Resistance mechanisms include: - **Man-PTS mutations**: Point mutations in the IIC or IID subunits that reduce SakP binding affinity. - **Man-PTS downregulation**: Reduced expression of the Man-PTS in the presence of alternative sugar sources. - **Membrane composition changes**: Alterations in lipid composition that reduce membrane fluidity and impair pore formation. To mitigate resistance, strategies include: - **Combination therapy**: Using SakP in combination with other bacteriocins (e.g., SakX) that target different receptors [2]. - **Engineered variants**: Developing SakP variants with improved receptor binding and reduced susceptibility to resistance mutations. - **Cyclical use**: Rotating SakP with other antimicrobials to prevent the selection of resistant strains. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for the *sakP* gene and SakP protein: | **Database** | **Accession/Identifier** | **Description** | |---|---|---| | NCBI Gene | 3930658 (L. sakei) | Gene entry for *sakP* | | NCBI Nucleotide | X65935.1 | Original *sakP* sequence from *L. sake* LTH673 | | UniProt | P35618 | Sakacin P precursor (SakP) | | RCSB PDB | 1O0S | NMR structure of sakacin P | | Ensembl Bacteria | Not applicable | Prokaryotic gene; not in Ensembl | | Gene Ontology (GO) | GO:0003796 (bacteriocin activity), GO:0016020 (membrane), GO:0005576 (extracellular region) | Functional annotations | | BioGRID | Not applicable | No protein-protein interaction data curated | | STRING | Not applicable | No interaction network available | | BACTIBASE | sakP | Bacteriocin database entry | | NCBI Taxonomy | 1597 (*Lactobacillus sakei*) | Source organism | ### 7.1 Sequence Analysis Tools For researchers working with *sakP*, the following tools are recommended: - **BLAST (NCBI)**: For homology searches and identification of *sakP* homologs in other LAB strains. - **Clustal Omega / MUSCLE**: For multiple sequence alignment of SakP variants. - **I-TASSER / AlphaFold**: For structural prediction of SakP variants with unknown conformations. - **SignalP**: For prediction of the double-glycine leader peptide cleavage site. - **TMHMM**: For transmembrane helix prediction (relevant for immunity protein SakE). ### 7.2 Experimental Resources - **ATCC / DSMZ**: Culture collections with *L. sakei* LTH673 (DSM 20017) and *L. curvatus* BCS35 strains. - **Addgene**: Plasmids for heterologous expression of *sakP* in *E. coli* or *Lactococcus lactis*. - **ProteomeXchange**: Mass spectrometry datasets for SakP identification and quantification. --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References [1] Tichaczek, P. S., Vogel, R. F., & Hammes, W. (1994). Cloning and sequencing of sakP encoding sakacin P, the bacteriocin produced by *Lactobacillus sake* LTH 673. *Microbiology*, 140(2), 361–367. [URL](https://www.semanticscholar.org/paper/dcb92091cdcdf34083a0db589618f07d33f85220) [2] Gómez-Sala, B., Muñoz-Atienza, E., Diep, D. B., Feito, J., del Campo, R., Nes, I. F., Herranz, C., Hernández, P. E., & Cintas, L. M. (2019). Biotechnological potential and in vitro safety assessment of *Lactobacillus curvatus* BCS35, a multibacteriocinogenic strain isolated from dry-salted cod (*Gadus morhua*). *LWT*, 112, 108233. [URL](https://www.semanticscholar.org/paper/584f08a537aeeebf0763a68d09972573c7f03015) [3] Boubakri, K., Idoui, T., Aristimuño Ficoseco, M. C., Segli, F., Castellano, P., Saavedra, L., & Vignolo, G. (2025). Autochthonous lactic acid bacteria from Kaddid as functional starter culture to improve quality and safety. *Discover Food*, 5(1), 12. [URL](https://www.semanticscholar.org/paper/82d391ade877a963c79fef966bd50f76c52a9d37) [4] Martinez, R. C., Staliano, C. D., Vieira, A. D. S., Villarreal, M. L. M., Todorov, S. D., Saad, S. M. I., & Franco, B. D. G. M. (2015). Bacteriocin production and inhibition of *Listeria monocytogenes* by *Lactobacillus sakei* subsp. *sakei* 2a in a potentially synbiotic cheese spread. *Food Microbiology*, 48, 143–152. [URL](https://www.semanticscholar.org/paper/02ed8e8a6b437f207af0e03f80eac1b4da42b7b1) [5] De Martino, V. D. (2016). Microbial cultures and leaf extracts of *Myrtus communis* L., strategies designed to ensure quality, safety and healthy properties of food products. *Scientific Publication*. [URL](https://www.semanticscholar.org/paper/5968ff9fa26a8a3f8228d2bf8d7bf268b2a5874e) [6] Hu, J., Winqvist, O., Flores-Morales, A., Wikström, A. C., & Norstedt, G. (2009). SOCS2 influences LPS induced human monocyte-derived dendritic cell maturation. *PLoS ONE*, 4(9), e7178. [URL](https://www.semanticscholar.org/paper/dedc9365b66f6bdf8dd462acaa5b3a275c09f699) --- **Author Contributions**: This reference manual was authored by Zubair Khalid, with editorial oversight from the scientific review board. The content was last updated on August 1, 2026, and reflects the current state of knowledge in bacteriocin research, structural biology, and antimicrobial resistance mitigation. All structural and functional data are derived from peer-reviewed literature and publicly available databases.